adobe stock - peterschreiber.media Despite the World Trade Organisation’s (WTO) ban of tariffs on pharmaceuticals, US President Donald Trump has announced he would consider imposing tariffs on pharmaceutical products. In a fast reaction, Swiss pharmaceutical giants Roche and Novartis, which are heavily dependent on the US market, have announced upcoming investments in the US as a production location by 2030.
French dairy heavyweight Bel Group has teamed up with Standing Ovation in a bid to transform surplus whey from cheese production into high-value casein proteins using precision fermentation. The collaboration is set to address the longstanding issue of under-utilised acid whey, a by-product that often goes to waste in the dairy sector.
uniqure NVAmsterdam-based uniQure NV’s gene therapy candidate AMT-130 has been granted FDA Breakthrough Therapy Designation for the treatment of the neurodegenerative Huntington’s disease.
RijksoverheidThe Netherlands has set itself an ambitious goal: to be among the global leaders in biotechnology by 2040. This vision is backed by an initial commitment of €1.3 billion in funding.
123rf.com/guniitaNLS Pharmaceutics secures US$2m equity funding and signs US$25m equity facility to support merger with Kadimastem (Israel) to combine expertise in aiming to become a leader in regenerative medicine in neurodegenerative disorders.
Zürich, 31 March 2025 –
wikicommonsUK focuses on digital health research: £600m (US$764m) for new data platform according to the five recommendations of the Sudlow report.
TIRmed Pharma ABTIRmed Pharma secures 4,3m€ to advance immunomodulatory treatment options for atopic dermatitis into clinical development. Stockholm-based TIRmed Pharma has closed this funding round, led by Sciety and its investment network, Sciety Venture Partners. The capital shall support the company’s progress toward clinical development of its novel treatment for atopic dermatitis.
Menarini GroupFrench ERBC and Menarini Biotech from Italy forge a new strategic alliance to accelerate biopharmaceutical development.
Freepik.comIn February 2025, the Federal Office of Public Health (FOPH) announced that the Masterplan in Biomedicine will be discontinued. This sends a troubling signal at a time of growing protectionism and potential trade conflicts. While other nations are actively collaborating with industry to secure the future of their pharmaceutical sectors, Switzerland is abandoning the only federal initiative aimed at improving conditions for biomedical research. The organisation scienceindustries calls for a renewed effort by the government to develop a new master plan.
Johnson & JohnsonThe case of the psoriasis antiinflammation antibody guselkumab is a story of deals and cooperation and selling and buying royalties to fuel other innovation paths. J&J is right in the middle of the game and has now full ownership while expanding the indications further.